SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dauntless who wrote (1499)1/6/1998 9:01:00 PM
From: BDR  Read Replies (2) of 7041
 
<<Also, back to statistics, would an MD consider Vasomax's response rate of
40% vs. the placebo's 17% to be a 23% or a 135% increase in response?>>

17%. I thought it was a response rate of 44% v. 25% for placebo which isn't a big improvement. Regardless of the placebo response, it means that even in the controlled environment of a study less than half the patients got the desired result. Somehow the studies by academics always show better results than we poor slobs out in the trenches get with our patients so I would predict that about a third would respond. That means two thirds are going to waste their time and money. I would like to see better odds since I am the guy who has to deal face to face with the patient.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News